David S. Russell, MD, PhD

• Catharine Duman
• Gilles Tamagnan
• Stephen Strittmatter

Alzheimer Disease; Huntington Disease; Movement Disorders; Parkinson Disease; Neurodegenerative Diseases

• In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s DiseaseBohorquez S, Constantinescu C, Manser P, Gunn R, Russell D, Tonietto M, Bullich S, Stephens A, Mueller A, Klein G, Teng E, Pickthorn K. In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063517.
• PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIHTempest P, Lin Y, Tai C, Ono M, Russell D, Sandiego C, Carroll V, Gunn R, Margolin R, Higuchi M, Jang M. PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063028.
• In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s DiseaseBohorquez S, Constantinescu C, Manser P, Gunn R, Russell D, Tonietto M, Bullich S, Stephens A, Mueller A, Klein G, Teng E, Pickthorn K. In Vivo Head‐To‐Head Comparison of [18F]GTP1 and [18F]PI2620 in Alzheimer’s Disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063513.
• PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIHTempest P, Lin Y, Tai C, Ono M, Russell D, Sandiego C, Gunn R, Carroll V, Margolin R, Kao T, Higuchi M, Jang M. PROGRESS IN DEVELOPING A LIGHT‐STABLE 4R TAU PET IMAGING AGENT: APN‐1701 FIH. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.063025.
• Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteersKielbasa W, Shcherbinin S, Goldsmith P, Phipps K, Biglan K, Mancini M, Russell D, Constantinescu C, Gunn R, Nuthall H, Mergott D, Lowe S, Collins E. Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.057774.
• Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to humanShcherbinin S, Kielbasa W, Dubois S, Lowe S, Phipps K, Tseng J, Kevin D, Natanegara F, Warner S, Dreyfus N, Lindsay‐Scott P, Hawk M, McDonald N, Zhang X, Gilmore J, Biglan K, Mergott D, Russell D, Gunn R, Constantinescu C, Nuthall H, Collins E. Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.040558.
• Perfusion-Phase 18 F-PI-2620 Tau-PET Imaging as a Surrogate Marker of Neuronal InjuryBeyer L, Nitschmann A, Barthel H, van Eimeren T, Unterrainer M, Sauerbeck J, Song M, Schroeter M, Russell D, Stephens A, Herms J, Levin J, Classen J, Höglinger G, Bartenstein P, Villemagne V, Drzezga A, Seibyl J, Sabri O, Brendel M. Perfusion-Phase 18 F-PI-2620 Tau-PET Imaging as a Surrogate Marker of Neuronal Injury. Nuklearmedizin - NuclearMedicine 2020, 59: 166. DOI: 10.1055/s-0040-1708352.
• Binding characteristics of 18 F-PI-2620 differentiate the clinically predicted tau isoform in suspected 3/4-repeat and 4-repeat tauopathiesSong M, Barthel H, van Eimeren T, Marek K, Beyer L, Sauerbeck J, Barbe M, Schroeter M, Russell D, Stephens A, Herms J, Levin J, Classen J, Höglinger G, Bartenstein P, Villemagne V, Drzezga A, Seibyl J, Sabri O, Brendel M. Binding characteristics of 18 F-PI-2620 differentiate the clinically predicted tau isoform in suspected 3/4-repeat and 4-repeat tauopathies. Nuklearmedizin - NuclearMedicine 2020, 59: 106. DOI: 10.1055/s-0040-1708171.
• 18 F-PI2620 Tau-PET in Progressive Supranuclear Palsy – A Multi-Center EvaluationBrendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, Sauerbeck J, Barbe M, Schroeter M, Russell D, Stephens A, Herms J, Levin J, Classen J, Höglinger G, Bartenstein P, Villemagne V, Drzezga A, Seibyl J, Sabri O. 18 F-PI2620 Tau-PET in Progressive Supranuclear Palsy – A Multi-Center Evaluation. Nuklearmedizin - NuclearMedicine 2020, 59: 89. DOI: 10.1055/s-0040-1708120.
• Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4)Beach T, Serrano G, Kremer T, Canamero M, Dziadek S, Sade H, Derkinderen P, Corbillé A, Letournel F, Munoz D, White C, Schneider J, Crary J, Sue L, Adler C, Glass M, Intorcia A, Walker J, Foroud T, Coffey C, Ecklund D, Riss H, Goßmann J, König F, Kopil C, Arnedo V, Riley L, Linder C, Dave K, Jennings D, Seibyl J, Mollenhauer B, Chahine L, Guilmette L, Russell D, Noyes-Lloyd C, Mitchell C, Smith D, Potter M, Case R, Lott D, Duffy A, Hogarth P, Cresswell M, Akhtar R, Purri R, Amara A, Blair C, Keshavarzian A, Marras C, Visanji N, Rothberg B, Oza V. Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). Journal Of Neuropathology & Experimental Neurology 2018, 77: 793-802. PMID: 30107604, PMCID: PMC6097838, DOI: 10.1093/jnen/nly056.
• T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMANTamagnan G, Barret O, Alagille D, Carroll V, Madonia J, Constantinescu C, SanDiego C, Papin C, Morley T, Russell D, McCarthy T, Zhang L, Gray D, Villalobos A, Lee C, Chen J, Seibyl J, Marek K. T156. IN VIVO CHARACTERIZATION OF THE FIRST AGONIST DOPAMINE D1 RECEPTORS PET IMAGING TRACER [18F]MNI-968 IN HUMAN. Schizophrenia Bulletin 2018, 44: s176-s176. PMCID: PMC5888516, DOI: 10.1093/schbul/sby016.432.
• O4‐07‐06: Approaches to quantitative analysis of the PET tau radiotracer [18F]AV1451Seibyl J, Barret O, Alagille D, Jennings D, Russell D, Marek K, Tamagnan G. O4‐07‐06: Approaches to quantitative analysis of the PET tau radiotracer [18F]AV1451. Alzheimer's & Dementia 2015, 11: p285-p285. DOI: 10.1016/j.jalz.2015.07.386.
• A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of BenefitBeal M, Oakes D, Shoulson I, Henchcliffe C, Galpern W, Haas R, Juncos J, Nutt J, Voss T, Ravina B, Shults C, Helles K, Snively V, Lew M, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters C, Figueroa A, Arkun A, Brodsky M, Ondo W, Hunter C, Jimenez-Shahed J, Palao A, Miyasaki J, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell D, Cotto C, Friedman J, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford D, Grimes D, Cote D, Conway J, Siderowf A, Evatt M, Sommerfeld B, Lieberman A, Okun M, Rodriguez R, Merritt S, Swartz C, Martin W, King P, Stover N, Guthrie S, Watts R, Ahmed A, Fernandez H, Winters A, Mari Z, Dawson T, Dunlop B, Feigin A, Shannon B, Nirenberg M, Ogg M, Ellias S, Thomas C, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser R, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi K, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson V, Markind S, Pelikan M, Perlmutter J, Hartlein J, Molho E, Evans S, Adler C, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey M, Hermanowicz N, Niswonger S, Shill H, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer K, Bergholte J, Propsom C, Stacy M, Field J, Mihaila D, Chilton M, Uc E, Sieren J, Simon D, Kraics L, Silver A, Boyd J, Hamill R, Ingvoldstad C, Young J, Thomas K, Kostyk S, Wojcieszek J, Pfeiffer R, Panisset M, Beland M, Reich S, Cines M, Zappala N, Rivest J, Zweig R, Lumina L, Hilliard C, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang U, Young J, Rao J, Cook M, Severt L, Boyar K. A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit. JAMA Neurology 2014, 71: 543-552. PMID: 24664227, DOI: 10.1001/jamaneurol.2014.131.
• Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson DiseaseKang J, Irwin D, Chen-Plotkin A, Siderowf A, Caspell C, Coffey C, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner C, Singleton A, Toga A, Chowdhury S, Mollenhauer B, Trojanowski J, Shaw L, Lasch S, Flagg E, Poewe W, Sherer T, Meunier C, Rudolph A, Casaceli C, Seibyl J, Mendick S, Schuff N, Uribe L, Yankey J, Crawford K, Scutti A, Casalin P, Malferrari G, Hawkins K, Russell D, Leary L, Factor S, Sommerfeld B, Hogarth P, Pighetti E, Williams K, Standaert D, Guthrie S, Hauser R, Jankovic J, Hunter C, Stern M, Darin A, Leverenz J, Baca M, Frank S, Thomas C, Richard I, Deeley C, Rees L, Sprenger F, Oertel W, Willeke D, Shill H, Fernandez H, Mule J, Berg D, Gauss K, Galasko D, Fontaine D, Mari Z, McCoy A, Brooks D, Shah B, Barone P, Isaacson S, James A, Espay A, Espay K, Rowe D, Ranola M. Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. JAMA Neurology 2013, 70: 1277-1287. PMID: 23979011, PMCID: PMC4034348, DOI: 10.1001/jamaneurol.2013.3861.
• Molecular Imaging in Parkinson DiseasePfeiffer R, Wszolek Z, Ebadi M, Jennings D, Russell D, Marek K, Seibyl J. Molecular Imaging in Parkinson Disease. 2012, 749-762. DOI: 10.1201/b12948-63.
• IC‐P‐100: Evaluation of the efficacy and safety of florbetaben PET in adults with down syndromeJennings D, Sabbagh M, Pfefferer C, Fristch A, Russell D, Seibyl J, Marek K, Reininger C. IC‐P‐100: Evaluation of the efficacy and safety of florbetaben PET in adults with down syndrome. Alzheimer's & Dementia 2011, 7: s49-s49. DOI: 10.1016/j.jalz.2011.05.065.
• Corrigendum to “Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice” [Brain Res. 1199 (2008) 148–158]Duman C, Schlesinger L, Russell D, Duman R. Corrigendum to “Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice” [Brain Res. 1199 (2008) 148–158]. Brain Research 2008, 1218: 313. DOI: 10.1016/j.brainres.2008.04.053.
• Protecting Motor Neurons from Toxic Insult by Antagonism of Adenosine A2a and Trk ReceptorsMojsilovic-Petrovic J, Jeong GB, Crocker A, Arneja A, David S, Russell D, Kalb RG. Protecting Motor Neurons from Toxic Insult by Antagonism of Adenosine A2a and Trk Receptors. Journal Of Neuroscience 2006, 26: 9250-9263. PMID: 16957081, PMCID: PMC6674510, DOI: 10.1523/jneurosci.1856-06.2006.
• Stress Vulnerability Induced by Neonatal Isolation and the Disturbance Between the Phosphorylation and Dephosphorylation of CREBMorinobu S, Tsuji S, Takahashi M, Russell D, Takahashi J, Tanaka K, Fujimaki K, Yamawaki S, Endoh S, Endoh M. Stress Vulnerability Induced by Neonatal Isolation and the Disturbance Between the Phosphorylation and Dephosphorylation of CREB. 2006, 37-45. DOI: 10.1007/4-431-29567-4_4.
• Regulation of affect by the lateral septum: implications for neuropsychiatrySheehan T, Chambers R, Russell D. Regulation of affect by the lateral septum: implications for neuropsychiatry. Brain Research Reviews 2004, 46: 71-117. PMID: 15297155, DOI: 10.1016/j.brainresrev.2004.04.009.
• Phospholipase Cγ in Distinct Regions of the Ventral Tegmental Area Differentially Modulates Mood-Related BehaviorsBolaños C, Perrotti L, Edwards S, Eisch A, Barrot M, Olson V, Russell D, Neve R, Nestler E. Phospholipase Cγ in Distinct Regions of the Ventral Tegmental Area Differentially Modulates Mood-Related Behaviors. Journal Of Neuroscience 2003, 23: 7569-7576. PMID: 12930795, PMCID: PMC6740761, DOI: 10.1523/jneurosci.23-20-07569.2003.
• Role for GDNF in Biochemical and Behavioral Adaptations to Drugs of AbuseMesser C, Eisch A, Carlezon W, Whisler K, Shen L, Wolf D, Westphal H, Collins F, Russell D, Nestler E. Role for GDNF in Biochemical and Behavioral Adaptations to Drugs of Abuse. Neuron 2000, 26: 247-257. PMID: 10798408, PMCID: PMC4451194, DOI: 10.1016/s0896-6273(00)81154-x.
• Brain‐Derived Neurotrophic Factor Induces Excitotoxic Sensitivity in Cultured Embryonic Rat Spinal Motor Neurons Through Activation of the Phosphatidylinositol 3‐Kinase PathwayFryer H, Wolf D, Knox R, Strittmatter S, Pennica D, O'Leary R, Russell D, Kalb R. Brain‐Derived Neurotrophic Factor Induces Excitotoxic Sensitivity in Cultured Embryonic Rat Spinal Motor Neurons Through Activation of the Phosphatidylinositol 3‐Kinase Pathway. Journal Of Neurochemistry 2000, 74: 582-595. PMID: 10646509, DOI: 10.1046/j.1471-4159.2000.740582.x.
• Regulation of Phospholipase Cγ in the Mesolimbic Dopamine System by Chronic Morphine AdministrationWolf D, Numan S, Nestler E, Russell D. Regulation of Phospholipase Cγ in the Mesolimbic Dopamine System by Chronic Morphine Administration. Journal Of Neurochemistry 1999, 73: 1520-1528. PMID: 10501197, PMCID: PMC1993239, DOI: 10.1046/j.1471-4159.1999.0731520.x.
• Discrete expression of insulin receptor substrate-4 mRNA in adult rat brainNuman S, Russell D. Discrete expression of insulin receptor substrate-4 mRNA in adult rat brain. Brain Research 1999, 72: 97-102. PMID: 10521603, DOI: 10.1016/s0169-328x(99)00160-6.
• Repeated stress increases catalytic TrkB mRNA in rat hippocampusNibuya M, Takahashi M, Russell D, Duman R. Repeated stress increases catalytic TrkB mRNA in rat hippocampus. Neuroscience Letters 1999, 267: 81-84. PMID: 10400217, DOI: 10.1016/s0304-3940(99)00335-3.
• Differential Regulation of Neurotrophin and trkReceptor mRNAs in Catecholaminergic Nuclei during Chronic Opiate Treatment and WithdrawalNuman S, Lane-Ladd S, Zhang L, Lundgren K, Russell D, Seroogy K, Nestler E. Differential Regulation of Neurotrophin and trkReceptor mRNAs in Catecholaminergic Nuclei during Chronic Opiate Treatment and Withdrawal. Journal Of Neuroscience 1998, 18: 10700-10708. PMID: 9852605, PMCID: PMC6793370, DOI: 10.1523/jneurosci.18-24-10700.1998.
• Antisense Oligonucleotides: New Tools for the Study of Brain FunctionRussell D, Widnell K, Nestler E. Antisense Oligonucleotides: New Tools for the Study of Brain Function. The Neuroscientist 1996, 2: 79-82. DOI: 10.1177/107385849600200207.
• Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens.Widnell K, Self D, Lane S, Russell D, Vaidya V, Miserendino M, Rubin C, Duman R, Nestler E. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens. Journal Of Pharmacology And Experimental Therapeutics 1996, 276: 306-15. PMID: 8558448.
• Influence of neurotrophic factors on morphine- and cocaine-induced biochemical changes in the mesolimbic dopamine systemBerhow M, Russell D, Terwilliger R, Beitner-Johnson D, Self D, Lindsay R, Nestler E. Influence of neurotrophic factors on morphine- and cocaine-induced biochemical changes in the mesolimbic dopamine system. Neuroscience 1995, 68: 969-979. PMID: 8545003, DOI: 10.1016/0306-4522(95)00207-y.
• Regulation of expression of cAMP response element-binding protein in the locus coeruleus in vivo and in a locus coeruleus-like cell line in vitro.Widnell K, Russell D, Nestler E. Regulation of expression of cAMP response element-binding protein in the locus coeruleus in vivo and in a locus coeruleus-like cell line in vitro. Proceedings Of The National Academy Of Sciences Of The United States Of America 1994, 91: 10947-10951. PMID: 7971989, PMCID: PMC45143, DOI: 10.1073/pnas.91.23.10947.